Algernon Pharmaceuticals Inc.
AGNPFDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NP-120 (Ifenprodil) | Phase 3 | COVID | - | - |
Ifenprodil | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Frequently asked questions
What is in Algernon Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Algernon Pharmaceuticals Inc.'s (AGNPF) pipeline across Phase 3, Phase 2. Its lead program is NP-120 (Ifenprodil) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Algernon Pharmaceuticals Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Algernon Pharmaceuticals Inc. (AGNPF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AGNPF biotech catalysts?→
Add AGNPF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Algernon Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.